Format

Send to

Choose Destination
Expert Opin Emerg Drugs. 2015 Jun;20(2):331-46. doi: 10.1517/14728214.2015.1036739.

Emerging therapies: angiogenesis inhibitors for ovarian cancer.

Author information

1
University of Cincinnati Medical Center, Division of Gynecologic Oncology , 222 Piedmont Ave, Suite 4100, Cincinnati, OH 45219 , USA.

Abstract

INTRODUCTION:

Patients with epithelial ovarian cancer (EOC) have a high rate of recurrence, and overall survival remains at ∼ 25%. There is a need for new treatments that can increase progression free survival and quality of life. Recent clinical trials focus on angiogenesis, VEGFs, and tyrosine kinase inhibitors that play a role in recurrence, metastasis, and ascites in EOC.

AREAS COVERED:

This review summarizes clinical rationale, mechanisms of action, and clinical data for angiogenesis inhibitors under evaluation in Phase II and III trials for EOC. Anti-angiogenesis agents reviewed in this paper include aflibercept, bevacizumab, cediranib, fosbretabulin, imatinib, nintedanib, pazopanib, saracatinib, sorafenib, sunitinib, and trebananib.

EXPERT OPINION:

These agents have particular rationale for potential use in EOC due to the molecular changes associated with EOC tumorigenesis, namely a significant increase in angiogenic activity. Due to the costs and toxicities associated with anti-angiogenics, biomarker or molecular signature selection strategy for patients who will most benefit would be ideal but no such strategy has been validated to date.

KEYWORDS:

VEGF; angiogenesis; bevacizumab; fallopian tube cancer; ovarian cancer; primary peritoneal cancer; tyrosine kinase inhibitors

PMID:
26001052
DOI:
10.1517/14728214.2015.1036739
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center